Haystack Oncology offers a ctDNA detection technology for early identification of residual, recurrent, or resistant disease using a low-error, personalized MRD testing platform.

Haystack Oncology applies the next-generation of ctDNA detection technology to deliver industry-leading sensitivity and specificity for transformative MRD testing

Exact Ventures

Alexandria Venture Investments

Bruker

Catalio Capital Management

Haystack Oncology

A recent study added to the research supporting the clinical utility of circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing in patients with cancer. The article, “Circulating Tumor DNA: A promising biomarker for predicting recurrence in patients with BRAF-negative melanoma,” by Lauren Aoude and others, was published in the Journal of Molecular Diagnostics.  

The authors examined whether a ctDNA liquid biopsy (blood test) could be used to find targetable tumor mutations in patients who have late-stage melanoma, potentially leading to alternative treatments and improved outcomes for these patients.  

Key findings of the study: 
• ctDNA variants were detected in 85% of patients with BRAF-negative melanoma 
• Patients with stage IV melanoma who had low ctDNA concentrations had significantly better disease-specific survival and progression-free survival 
• Patients with a high ctDNA concentration and any detectable ctDNA variants had the worst prognosis 
• Changes in ctDNA concentration over time correlated with treatment response and disease progression 

The authors concluded that ctDNA liquid biopsies may be used to identify recurrent disease and detect targetable variants in patients with late-stage melanoma.  

Read the full study at https://hubs.la/Q027W0yn0

MRD testing demands the most sensitive ctDNA detection. Haystack MRD™ uses the next generation of ctDNA detection technology to see through the noise and uncover residual, recurrent, and resistant disease earlier. 

For circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing, the type of mutations tracked matters.  

 When designing a patient's personalized panel for an MRD test, Haystack's process is very deliberate in identifying and prioritizing truncal mutations—those mutations at the trunk of the “evolutionary tree” in the tumor.  

 By prioritizing mutations that drive the patient’s disease and that are present in both the primary tumor as well as any distant metastases, Haystack MRD can provide a more accurate picture of overall disease burden, resulting in more confident MRD results. 

Learn more at https://hubs.la/Q025sHTx0

Haystack Oncology is proud to be part of the 2023 European Society for Medical Oncology conference (#ESMO2023).  

Learn about our ultrasensitive #MRD technology. Add leverage to your drug discovery pipeline and accelerate biopharma innovation. Booth 586. Learn more at https://hubs.la/Q026fh160

Quest is proud to support #BreastCancerAwarenessMonth and recognize everyone involved in the fight against #breastcancer. According to the 
American Cancer Society, 1 in 8 women will be diagnosed with invasive breast cancer in their lifetime. Early detection can help save lives. As a single-source solutions provider, we offer tests for screening, diagnosis, treatment selection, and monitoring. Learn more: QuestHereditaryCancer.com

Haystack MRD™ uses a personalized, tumor-informed approach for minimal residual disease testing, meaning that a sample of each patient’s tumor is used to design an #MRD panel specific to that patient. In contrast, some MRD tests are tumor-naive, or tumor-agnostic, using the same panel of mutations for all patients.  

Read our blog post about the important differences between tumor-informed and tumor-naive MRD testing: https://hubs.la/Q021PSts0

COM:HAYSTACKONCOLOGY

Haystack Oncology

Analysis Not Available